Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

Aiming to improve bioavailability and optimize the therapeutic effect of Clearmind’s psychedelic-based treatments

Vancouver, Canada, March 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that it has signed a non-binding Letter of Intent (LOI) with Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, to develop a novel intranasal formulation for its psychedelic-based treatment applications.

Read more at globenewswire.com